<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83909">
  <stage>Registered</stage>
  <submitdate>9/05/2009</submitdate>
  <approvaldate>3/06/2009</approvaldate>
  <actrnumber>ACTRN12609000410257</actrnumber>
  <trial_identification>
    <studytitle>A randomized clinical trial of continuous positive airway pressure (CPAP) in the treatment of acute cardiogenic pulmonary oedema (APO) patients in the pre-hospital setting</studytitle>
    <scientifictitle>A randomized clinical trial assessing survival rates in patients with acute cardiogenic pulmonary oedema (ACPO) who are treated with continuous positive airway pressure (CPAP) in the pre-hospital setting</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Cardiogenic Pulmonary Oedema</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Continuous postive airway pressure (CPAP) at 10 cm H20 with face mask will be used for patients in acute respiratory distress with clnical diagnosis of acute cardiogenic pulmonary oedema) ACPO. The duration of the treatment will be time transported and treated by paramedics. All other treatments will be cosistant between groups (Glycerine trinitrate (GTN) spray incremental doses every 5 min of 400 mcg up to 1600 mcg sublingual with repreated 1600 mcg every 5 min as long as BP &gt;100 systolic, Frusemide dose 40 mg increments every 20 min to max 80 mg intravenous)</interventions>
    <comparator>inspired positive pressure ventilation (IPPV) with bag valve mask will be used for patients in acute respiratory distress with clnical diagnosis of acute cardiogenic pulmonary oedema) ACPO. The duration of the treatment will be time transported and treated by paramedics. All other treatments will be cosistant between groups (GTN, Frusemide)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mortality</outcome>
      <timepoint>During this admission and treatement episode</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>requirement for invasive ventilation (Endotracheal tube) - Patient who do not support there airways and have a reducing level of consciousness may require invasive ventilation this will be a clincial judgement by the paramedics.</outcome>
      <timepoint>During this admission and treatment episode</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Arterial blood gas (Partial pressure oxygen (PO2), Partial pressure carbon dioxide (pCO2), Bicarbonate, pH)</outcome>
      <timepoint>within 30 min upon arrival to hospital and no other assessment of blood gases will be reviewed as the pre-hosptial treatment has ceased.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>requirement for Iintesive care unit (ICU) admisson</outcome>
      <timepoint>During this admission and treatment episode</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vital signs (Blood Pressure (BP), Respiratory Rate - clinically by paramedics, Oxygen Saturation - portable machine pulse oximetry, Heart rate, Glascow coma scale (GCS)</outcome>
      <timepoint>During this admission and treatment episode (continuously for saturations and at the discretion of the paramedics for the other outcomes)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age over 18 years
Crackles on auscultation of the lungs
Breathlessness and increased work of breathing
History of ischemic heart disease (IHD) or risk factor contributing to IHD</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Other respiratory conditions (particularly asthma and Chronic obstructive pulmonary disease (COPD)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Random concealed evelopes containing cards with treatement allocation which will be drawn after assessment of patient and decided they meet the inclusion criteria</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate>4/07/2009</actualstartdate>
    <anticipatedenddate>31/12/2010</anticipatedenddate>
    <actualenddate>30/06/2010</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Tasmanian Ambulance Service department of health and human services</primarysponsorname>
    <primarysponsoraddress>1 Melville street 
Hobart TAS 7000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Fisher and paykel Healthcare</fundingname>
      <fundingaddress>PO Box 167
36-40 New Street
Ringwood VIC 3134</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>The NHMRC Centre of Research Excellence (CRE) University of Tasmania, Australia</fundingname>
      <fundingaddress>Menzies Research Institute Tasmania, University of Tasmania, Private Bag 23 Hobart, Tasmania Australia 7001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Fisher and Paykel Healthcare</sponsorname>
      <sponsoraddress>PO Box 167
36-40 New Street
Ringwood VIC 3134</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Purpose of trial is to compare Continuous positive airway pressure (CPAP) versus conventional therapy of inspired postive pressure ventilation with bag valve mask.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Ethics Application Form (NEAF)- Tasmania Health and Medical Human Research Ethics Committee</ethicname>
      <ethicaddress>Human Research Ethics Committee Administration
University of Tasmania
Office of Research Services
Private Bag 01
Hobart Tasmania 7001</ethicaddress>
      <ethicapprovaldate>14/11/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Austin</name>
      <address>Menzies Research Institute 
Private Bag 23
Hobart TAS 7001</address>
      <phone>61 3 6226 7757</phone>
      <fax />
      <email>maaustin@utas.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Austin</name>
      <address>Menzies Research Institute 
Private Bag 23
Hobart TAS 7001</address>
      <phone>61 3 6226 7757</phone>
      <fax />
      <email>maaustin@utas.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michael Austin</name>
      <address>Menzies Research Institute 
Private Bag 23
Hobart TAS 7001</address>
      <phone>61 3 6226 7757</phone>
      <fax />
      <email>maaustin@utas.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Austin</name>
      <address>Menzies Research Institute Tasmania, University of Tasmania, Private Bag 23 Hobart, Tasmania Australia 7001</address>
      <phone>61 3 6226 7757</phone>
      <fax />
      <email>maaustin@utas.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>